Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3841136 and Tirzepatide for Weight Management in Adults With Obesity/Overweight and Type 2 Diabetes
NCT06603571Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2024
- Primary completion
- Jul 2026
- Modality
- Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of eloralintide in obesity, type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Sep 2024; status: completed.
02
Drugs
eloralintide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06603571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06603571.